Ultrastructural Evidence of Glycosphingolipid Degradation After Enzyme Replacement Therapy in Patients With Fabry Disease

Circ J. 2019 Sep 25;83(10):2081. doi: 10.1253/circj.CJ-19-0127. Epub 2019 Mar 29.

Authors

Affiliations

¹ Cardiovascular Medicine, Nara Medical University.
² Department of Internal Medicine, Asahi University School of Dentistry.
³ Department of Cardiology, Gifu University Graduate School of Medicine.
⁴ Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine.
⁵ Cardiovascular Medicine, Nara City Hospital.
⁶ Department of Community-based Medicine, Nara Medical University.

PMID: 30930427
DOI: 10.1253/circj.CJ-19-0127

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Enzyme Replacement Therapy*
Fabry Disease / drug therapy*
Fabry Disease / enzymology
Fabry Disease / pathology
Female
Glycosphingolipids / metabolism*
Humans
Hydrolysis
Male
Middle Aged
Myocytes, Cardiac / drug effects*
Myocytes, Cardiac / enzymology
Myocytes, Cardiac / ultrastructure
Treatment Outcome
alpha-Galactosidase / administration & dosage*
alpha-Galactosidase / metabolism

Substances

Glycosphingolipids
alpha-Galactosidase

Supplementary concepts

Fabry Disease, Cardiac Variant